Observation of the curative effect and safety of insulin aspart in the treatment of newly diagnosed gestational diabetes mellitus

Abstract

Objective To evaluate the curative effect and safety of insulin aspart in the treatment of newly diagnosed gestational diabetes mellitus (GDM).Methods Thirty - two cases of pregnant women with newly diagnosed GDM were divided into insulin aspart (novorapid) treating group (observation group) of 18 cases and short - acting biosynthetic human insulin ( novolin R) treating group ( contrast group) of 15 cases.Patients in both groups were injected with insulin pump with a period of treatment from definite diagnosis to parturition.The fasting capillary blood glucose,postprandial capillary blood glucose,presleep capillary blood glucose,HbA1c,time of blood sugar reaching standard,insulin applying dosage,hypoglycemia occurring rate,maternal and fetal complications in perinatal between the two groups before and after treatment were observed.Results ①The fasting capillary blood glucose,postprandial capillary blood glucose,presleep capillary blood glucose,HbA1 c in the two groups declined distinctly (P ＜ 0.01 ) compared to state before treatment,and the postprandial capillary blood glucose in the observation group declined more distinctly compared with that in the contrast group (P ＜ 0.05 ) ;while the difference of fasting capillary blood glucose,presleep capillary blood glucose and HbA1 c between the two groups had no statistical significance (P ＞ 0.05 ).②The time of blood reaching standard in the observation group was obviously shorter than that in the contrast group (P ＜ 0.01 ),and the average daily applying dosage of insulin was distinctly less than that in the contrast group (P ＜ 0.05 ),also its hypoglycemia occurring rate was much lower than that of the contrast group (P ＜ 0.01 ).③The maternal and fetal complications in perinatal between the two groups had no statistical significance (P ＞0.05).Conclusions Novorapid can more effectively control the postprandial capillary blood glucose with less insulin applying dosage,shorter time reaching standard and lower hypoglycemia occurring rate than Novolin R.Novorapid is safe and effective in treating GDM,which provides a better choice for patients with GDM in controlling blood glucose. Key words: Gestational diabetes mellitus; Insulin aspart; Novorapid